Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial
Background - Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. - Patients and methods - This randomized, double-blind, multicenter trial (NCT0310...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2023
|
| In: |
Annals of oncology
Year: 2023, Jahrgang: 34, Heft: 12, Pages: 1152-1164 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2023.09.3110 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2023.09.3110 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753423040073 
|
| Verfasserangaben: | E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Mądry, R. Glasspool, I. Vergote, J. Korach, S. Lheureux, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M. J. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I. Ray-Coquard & A. Redondo, on behalf of the OReO/ENGOT-ov38 investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1884720544 | ||
| 003 | DE-627 | ||
| 005 | 20240703161751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240402s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.09.3110 |2 doi | |
| 035 | |a (DE-627)1884720544 | ||
| 035 | |a (DE-599)KXP1884720544 | ||
| 035 | |a (OCoLC)1443657921 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pujade-Lauraine, Éric |e VerfasserIn |0 (DE-588)173497586 |0 (DE-627)698410319 |0 (DE-576)134342623 |4 aut | |
| 245 | 1 | 0 | |a Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) |b a phase IIIb trial |c E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Mądry, R. Glasspool, I. Vergote, J. Korach, S. Lheureux, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M. J. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I. Ray-Coquard & A. Redondo, on behalf of the OReO/ENGOT-ov38 investigators |
| 264 | 1 | |c December 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 4. Oktober 2023, Artikelversion: 10. Dezember 2023 | ||
| 500 | |a Gesehen am 02.04.2024 | ||
| 520 | |a Background - Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the standard of care for some patients with advanced ovarian cancer. We evaluated the efficacy and safety of PARP inhibitor rechallenge. - Patients and methods - This randomized, double-blind, multicenter trial (NCT03106987) enrolled patients with platinum-sensitive relapsed ovarian cancer who had received one prior PARP inhibitor therapy for ≥18 and ≥12 months in the BRCA-mutated and non-BRCA-mutated cohorts, respectively, following first-line chemotherapy or for ≥12 and ≥6 months, respectively, following a second or subsequent line of chemotherapy. Patients were in response following their last platinum-based chemotherapy regimen and were randomized 2 : 1 to maintenance olaparib tablets 300 mg twice daily or placebo. Investigator-assessed progression-free survival (PFS) was the primary endpoint. - Results - Seventy four patients in the BRCA-mutated cohort were randomized to olaparib and 38 to placebo, and 72 patients in the non-BRCA-mutated cohort were randomized to olaparib and 36 to placebo; >85% of patients in both cohorts had received ≥3 prior lines of chemotherapy. In the BRCA-mutated cohort, the median PFS was 4.3 months with olaparib versus 2.8 months with placebo [hazard ratio (HR) 0.57; 95% confidence interval (CI) 0.37-0.87; P = 0.022]; 1-year PFS rates were 19% versus 0% (Kaplan-Meier estimates). In the non-BRCA-mutated cohort, median PFS was 5.3 months for olaparib versus 2.8 months for placebo (HR 0.43; 95% CI 0.26-0.71; P = 0.0023); 1-year PFS rates were 14% versus 0% (Kaplan-Meier estimates). No new safety signals were identified with olaparib rechallenge. - Conclusions - In ovarian cancer patients previously treated with one prior PARP inhibitor and at least two lines of platinum-based chemotherapy, maintenance olaparib rechallenge provided a statistically significant, albeit modest, PFS improvement over placebo in both the BRCA-mutated and non-BRCA-mutated cohorts, with a proportion of patients in the maintenance olaparib rechallenge arm of both cohorts remaining progression free at 1 year. | ||
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a OReO/ENGOT-ov38 | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a platinum-sensitive relapsed ovarian cancer | |
| 650 | 4 | |a rechallenge | |
| 700 | 1 | |a Selle, F. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scambia, G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Asselain, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Lindemann, K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colombo, N. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mądry, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Glasspool, R. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vergote, Ignace B. |e VerfasserIn |0 (DE-588)173237657 |0 (DE-627)698157044 |0 (DE-576)134087143 |4 aut | |
| 700 | 1 | |a Korach, J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lheureux, S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dubot, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oaknin, A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zamagni, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heitz, Florian |d 1976- |e VerfasserIn |0 (DE-588)13714220X |0 (DE-627)590336347 |0 (DE-576)30237051X |4 aut | |
| 700 | 1 | |a Gladieff, L. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rubio-Pérez, M. J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scollo, P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Blakeley, C. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Shaw, B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ray-Coquard, I. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Redondo, A. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 34(2023), 12 vom: Dez., Seite 1152-1164 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) a phase IIIb trial |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:12 |g month:12 |g pages:1152-1164 |g extent:13 |a Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) a phase IIIb trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2023.09.3110 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753423040073 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240402 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 5 | ||
| 999 | |a KXP-PPN1884720544 |e 4506329082 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"December 2023"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"a phase IIIb trial","title_sort":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38)","title":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38)"}],"person":[{"family":"Pujade-Lauraine","given":"Éric","display":"Pujade-Lauraine, Éric","role":"aut"},{"display":"Selle, F.","family":"Selle","given":"F.","role":"aut"},{"role":"aut","given":"G.","family":"Scambia","display":"Scambia, G."},{"given":"B.","family":"Asselain","display":"Asselain, B.","role":"aut"},{"display":"Marmé, Frederik","family":"Marmé","given":"Frederik","role":"aut"},{"role":"aut","given":"K.","family":"Lindemann","display":"Lindemann, K."},{"role":"aut","display":"Colombo, N.","given":"N.","family":"Colombo"},{"display":"Mądry, R.","given":"R.","family":"Mądry","role":"aut"},{"display":"Glasspool, R.","given":"R.","family":"Glasspool","role":"aut"},{"family":"Vergote","given":"Ignace B.","display":"Vergote, Ignace B.","role":"aut"},{"role":"aut","display":"Korach, J.","family":"Korach","given":"J."},{"family":"Lheureux","given":"S.","display":"Lheureux, S.","role":"aut"},{"family":"Dubot","given":"C.","display":"Dubot, C.","role":"aut"},{"role":"aut","display":"Oaknin, A.","family":"Oaknin","given":"A."},{"family":"Zamagni","given":"C.","display":"Zamagni, C.","role":"aut"},{"display":"Heitz, Florian","given":"Florian","family":"Heitz","role":"aut"},{"family":"Gladieff","given":"L.","display":"Gladieff, L.","role":"aut"},{"display":"Rubio-Pérez, M. J.","family":"Rubio-Pérez","given":"M. J.","role":"aut"},{"role":"aut","family":"Scollo","given":"P.","display":"Scollo, P."},{"family":"Blakeley","given":"C.","display":"Blakeley, C.","role":"aut"},{"display":"Shaw, B.","family":"Shaw","given":"B.","role":"aut"},{"role":"aut","display":"Ray-Coquard, I.","given":"I.","family":"Ray-Coquard"},{"display":"Redondo, A.","given":"A.","family":"Redondo","role":"aut"}],"note":["Online verfügbar: 4. Oktober 2023, Artikelversion: 10. Dezember 2023","Gesehen am 02.04.2024"],"name":{"displayForm":["E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Mądry, R. Glasspool, I. Vergote, J. Korach, S. Lheureux, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M. J. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I. Ray-Coquard & A. Redondo, on behalf of the OReO/ENGOT-ov38 investigators"]},"relHost":[{"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"recId":"320428796","corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"part":{"volume":"34","pages":"1152-1164","extent":"13","year":"2023","issue":"12","text":"34(2023), 12 vom: Dez., Seite 1152-1164"},"disp":"Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38) a phase IIIb trialAnnals of oncology","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"pubHistory":["1.1990 -"],"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedKey":"1990","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"]}],"id":{"doi":["10.1016/j.annonc.2023.09.3110"],"eki":["1884720544"]},"recId":"1884720544","language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"13 S."}]} | ||
| SRT | |a PUJADELAURMAINTENANC2023 | ||